A resurgence in research into drugs for psychiatric and neurological conditions could be coming soon, as the demand for treatments for diseases such as Alzheimers, ALS, Parkinson’s and psychiatric disorders continues to rise and increased scientific knowledge is paving the way for more effective drugs.

Investors last year contributed $3.3 billion to firms working on drugs for neurological or psychiatric illnesses, more than in any of the last 10 years, according to an article in Forbes. Some big drug companies, including Johnson & Johnson, Roche and Novartis, are rejuvenating their efforts. New medicines for severe depression, psychosis and schizophrenia could make it to market within the next few years, and treatments for Alzheimer’s, Parkinson’s and some forms of autism could follow, the Forbes article notes.

Source: Forbes